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STATEMENT OF TRANSLATIONAL RELEVANCE 
Numerous studies have attempted to identify common inherited variants that 
affect survival in patients with colorectal cancer (CRC). However, none of the 
proposed prognostic biomarkers have been confirmed, often because the 
original studies have used small numbers of patients and/or not used 
independent validation cohorts. We have overcome these limitations and 
sought robust prognostic biomarkers by analysing 20 genome-wide significant 
CRC-risk alleles in a large training phase cohort (n=2083 patients with CRC), 
with subsequent validation of positive associations in an independent study 
group (n=5552 patients with CRC). We found that rs9929218 (intron 2 of 
CDH1, encoding E-cadherin) was robustly associated with survival. Patients 
homozygous for the minor allele (AA genotype, ~8% of patients) had worse 
survival, which equated to a median decrease in life expectancy of 4.3 
months, and was independent of known prognostic factors. Our findings 
clearly demonstrate that common germline variants influence life expectancy 
in patients with CRC.  
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ABSTRACT 
Purpose 
Genome wide association studies have identified numerous loci associated 
with colorectal cancer (CRC) risk. Several of these have also been associated 
with patient survival, although none have been validated. Here, we used large 
independent training and validation cohorts to identify robust prognostic 
biomarkers for CRC. 
 
Experimental Design 
In our training phase, we analysed 20 CRC-risk single nucleotide 
polymorphisms (SNPs) from 14 genome wide associated loci, for their effects 
on survival in 2083 patients with advanced CRC. A Cox survival model was 
used, stratified for treatment, adjusted for known prognostic factors and 
corrected for multiple testing. Three SNPs were subsequently analysed in an 
independent validation cohort of 5552 CRC patients. A validated SNP was 
analysed by disease stage and response to treatment. 
 
Results 
Three variants associated with survival in the training phase; however, only 
rs9929218 at 16q22 (intron 2 of CDH1, encoding E-cadherin) was significant 
in the validation phase. Patients homozygous for the minor allele (AA-
genotype) had worse survival (training phase HR=1.43, 95%CI 1.20-1.71, 
P=5.8x10-5; validation phase HR=1.18, 95%CI 1.01-1.37, P=3.2x10-2; 
combined HR=1.28 95%CI 1.14-1.43, P=2.2x10-5). This effect was 
independent of known prognostic factors, and was significant amongst 
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patients with stage 4 disease (P=2.7x10-5). rs9929218 was also associated 
with poor response to chemotherapy (P=3.9x10-4). 
 
Conclusions 
We demonstrate the potential of common inherited genetic variants to inform 
patient outcome and show that rs9929218 identifies ~8% of CRC patients with 
poor prognosis. rs9929218 may affect CDH1 expression and E-cadherin plays 
a role in epithelial-mesenchymal transition providing a mechanism underlying 
its prognostic potential.
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INTRODUCTION 
Worldwide, over a million people are diagnosed with colorectal cancer (CRC) 
each year. Several factors influence survival after diagnosis, but the only 
routinely used prognostic marker is clinical stage which combines depth of 
tumour invasion, nodal status and distant metastasis (1). Other factors 
thought to influence prognosis include lifestyle (2,3), systemic inflammatory 
response to the tumour (4), the tumour immunologic microenvironment (5) 
and the tumour’s somatic molecular profile (6-9). 
 
The search for inherited factors that affect prognosis has primarily focussed 
on candidate genes that either function within the pharmacological pathways 
of the chemotherapeutic agents used in the treatment of CRC (10,11) or that 
influence tumour progression (12). Recently, high-throughput single 
nucleotide polymorphism (SNP) arrays have been used to search for CRC-
susceptibility alleles by genome-wide association studies (GWAS) and, to-
date, identified 27 genome-wide significant low penetrance loci mapping to 
8q24 (13,14), 18q21 (15,16), 15q13 (17,18), 11q23 (16), 10p14 (19), 8q23 
(19), 14q22 (20), 16q22 (20), 19q13 (20), 20p12 (20,21), 1q41 (22), 3q26 
(22), 12q13 (22), 20q13 (22), 6p21 (23), 11q13 (23), Xp22 (23), 2q32 (24), 
12p13 (21,25,26), 5q31 (21), 1q25.3 (24,25), 10q24 (25), 10q22 (26), 10q25 
(26), 11q12 (26), 17p13 (26) and 19q13 (26). Studies have suggested that 
some of these risk alleles may also affect patient survival (27-32); however, 
none of these survival findings, nor any prognostic biomarkers identified 
through the candidate gene analyses, have been validated in independent 
studies (33-35). 
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Here, we sought robust biomarkers of patient survival by analysing 20 
genome-wide significant CRC-susceptibility SNPs in a large training phase 
cohort, with subsequent validation of positive associations in an independent 
study group. 
 
MATERIALS AND METHODS 
Samples 
Training phase 
We prepared blood DNA samples from unrelated patients with advanced 
(Stage 4) CRC (aCRC) from the MRC clinical trial COIN (NCT00182715) (36). 
All patients had either previous or current histologically confirmed primary 
adenocarcinomas of the colon or rectum, together with clinical or radiological 
evidence of advanced and/or metastatic disease, or had 
histologically/cytologically confirmed metastatic adenocarcinomas, together 
with clinical and/or radiological evidence of a colorectal primary tumour. 
Patients were randomised 1:1:1 to receive continuous oxaliplatin and 
fluoropyrimidine chemotherapy (Arm A), continuous chemotherapy plus 
cetuximab (Arm B), or intermittent chemotherapy (Arm C). All patients gave 
informed consent for their samples to be used for bowel cancer research 
(approved by REC [04/MRE06/60]). 
 
Validation phase 
The validation phase consisted of samples from several different trials or 
prospective cohort studies. COINB is a MRC-funded phase II trial assessing 
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cetuximab efficacy in intermittent oxaliplatin-fluoropyrimidine chemotherapy of 
aCRC (NCT00640081) (37). FOCUS2 is a trial for patients with unpretreated 
aCRC judged unfit for full-dose combination chemotherapy (NCT00070213). 
FOCUS3 is a trial determining the feasibility of molecular selection of therapy 
using KRAS, BRAF and topoisomerase-1 in aCRC (NCT00975897). 
PICCOLO is a trial of the treatment for fluorouracil-resistant aCRC 
(NCT00389870) (patients from COIN or COINB that were subsequently 
recruited into PICCOLO were excluded). VICTOR is a trial of rofecoxib as 
post-adjuvant therapy for CRC (NCT00031863). Six prospective cohort 
studies from the Genetics and Epidemiology of Colorectal Cancer Consortium 
(GECCO) (24,38) were also included: the Health Professionals Follow-up 
Study (HPFS), the Nurses’ Health Study (NHS), the Physicians’ Health Study 
(PHS), the VITamins And Lifestyle Study (VITAL), the Women’s Health 
Initiative (WHI) and the Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial (PLCO) (see Supplementary Information for references). All of 
these studies used a prospective design, with follow-up for incident cancer 
diagnoses and survival outcomes. Cases of incident CRC arising in these 
studies were identified from self-report and confirmed by their medical records 
(HPFS, NHS, PHS, PLCO, WHI) and/or linkage to cancer registries (VITAL). 
Two subsets of cases were genotyped in the WHI: WHI1 included colon 
cancer patients diagnosed before September 2005 and WHI2 included 
unrelated CRC patients diagnosed before August 2009. Two subsets of cases 
were also genotyped in PLCO: PLCO1 included colon cancer patients and 
PLCO2 included unrelated CRC cases. All participants provided informed 
consent for genetic testing, and all studies were approved by their respective 
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Institutional Review Boards. Protocols for assessing survival in the GECCO 
studies have been described previously (see Supplementary Information for 
references). 
 
Genotyping 
Training phase 
Genotyping of fifteen CRC risk alleles (rs6691170 and rs6687758 at 1q41, 
rs10936599 at 3q26, rs4444235 and rs1957636 at 14q22, rs9929218 at 
16q22, rs10411210 at 19q13, rs961253 at 20p12, rs10795668 at 10p14, 
rs3802842 at 11q23, rs4925386 at 20q13, rs4939827 at 18q21, rs16892766 
at 8q23, rs4779584 at 15q13 and rs6983267 at 8q24) was performed by 
Illumina's Fast-Track Genotyping Services (San Diego, CA) using their high 
throughput BeadArray™ technology. rs4925386 failed genotyping. For the 
remaining 14 SNPs, genotyping concordance rates for duplicate samples 
(n=110) was 100% (1540/1540 genotypes), GenTrain scores ranged from 
0.6814 to 0.9500 and the overall genotype success rate was 99.44% 
(28868/29032 genotypes were called successfully). Genotyping of rs4925386 
at 20q13, rs4813802 at 20p12 and, rs16969681 and rs11632715 at 15q13 
was carried out by LGC genomics using their KASPar technology with a 
genotype success rate of 99.17% (8253/8322 genotypes called successfully) 
and concordance rate for duplicate samples (n=94) of 100% (376/376). 
Genotyping of rs11169552 and rs7136702 at 12q13 was carried out by 
Geneservice (Nottingham, UK) using TaqMan assays (Applied Biosystems) 
with a genotype success rate of 95.66% (3966/4146 genotypes called 
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successfully) and concordance rate for duplicate samples (n=94) of 100% 
(188/188). 
 
Validation phase 
rs16892766, rs9929218 and rs10795668 were genotyped in patients from 
COINB, FOCUS2, FOCUS3 and PICCOLO by LGC genomics (KASPar 
technology). In VICTOR, genotyping was carried out on Illumina 
HumanHap300 arrays and rs9929218 was directly genotyped, rs16892766 
was imputed and rs706771 was genotyped as a proxy for rs10795668 
(R2=0.965, D'=1). All three SNPs were genotyped in cases from HPFS, NHS, 
and PHS using the TaqMan Open Array SNP genotyping platform. For the 
other GECCO studies, genotyping was performed on Illumina 300/240S 
(PLCO1), 550K (WHI1), 610K (WHI1, PLCO1), and HumanCytoSNP (VITAL, 
WHI2, PLCO2) arrays; rs9929218 was directly genotyped on these platforms 
in all studies, and, rs16892766 and rs10795668 were directly genotyped on 
the platform used in WHI1 and PLCO1, and imputed (using MACH and 
HapMap2 Release 24) in WHI2, VITAL, and PLCO2. Note – different 
genotyping platforms were often used because susceptibility SNPs were 
identified and assayed at different times by different investigators. 
 
Statistical analyses 
All SNPs were tested for their genotypes being consistent with the Hardy 
Weinberg Equilibrium (HWE) using a Pearson chi-square test. Linkage 
disequilibrium (LD) was examined using Haploview version 4.2. For survival 
analyses of the training phase, we used a Cox survival model with overall 
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survival (time from trial randomisation to death) as the primary measure. A co-
dominant model was applied, analyses were stratified for treatment arm and 
type of fluoropyrimidine used, and P-values were corrected for multiple testing 
by Bonferroni correction. Significant SNPs were tested for independence to 
known prognostic factors using a closed-test procedure multiple fractional 
polynomial model with P<0.05 and the best-fitting genotype model (dominant 
or recessive) was identified. For survival analyses in the validation phase, 
time from randomisation to death (overall survival) was used for COINB, 
FOCUS2, FOCUS3, PICCOLO and VICTOR, and time from diagnosis to 
death for HPFS, NHS, PHS, VITAL, WHI and PLCO. A Cox survival model 
was fitted to the data from each trial or study separately, and an overall 
pooled result was calculated using a fixed-effects inverse-variance meta-
analysis approach. Heterogeneity was assessed using the Q and I-squared 
statistics. If the pooled validation data generated a significant result, additional 
analyses were conducted: (i) a further meta-analysis including the training and 
validation data together, (ii) a sensitivity analysis replacing time from 
randomisation to death (considered left-truncated at randomisation to account 
for the fact that randomisation is conditional upon survival from diagnosis) with 
time from diagnosis to death - for those trials for which this information was 
available (COIN, COINB and FOCUS3; n=2446 patients genotyped with 
survival data), and, (iii) the effect on 12-week response to chemotherapy in 
COIN Arms A and C (those arms not confounded by treatment with 
cetuximab; n=1369 patients genotyped with this data). Response was defined 
as complete response or partial response at 12-weeks and non-response was 
defined as stable disease or progressive disease. 
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RESULTS 
Training phase 
We analysed blood DNA samples from 2083 unrelated patients with aCRC 
from the UK national trial COIN (36). In total, 34% of patients were female with 
a mean age at diagnosis of 62 years (range 18-84 years, Table 1). We 
assayed twenty independent, genome-wide significant, CRC-risk alleles 
(13,15-17,19,20,22) representing 14 loci; with a single SNP at nine loci, two 
SNPs at four loci and three SNPs at one locus (loci with ≥2 SNPs contain 
multiple independent risk alleles) (20,22). Fifteen SNPs were genotyped using 
the Illumina GoldenGate platform (one failed), four (including a repeat of the 
failed SNP) were successfully genotyped using KASPar technology and two 
were successfully genotyped using Taqman assays. All 20 SNPs, apart from 
rs7136702 (P=0.027), had genotype distributions consistent with the HWE 
with no imbalances between the treatment arms or according to the somatic 
mutation status of the CRCs (42.27%, 9.01% and 3.56% of CRCs were 
KRAS, BRAF and NRAS mutant, respectively) (39). 
 
Fourteen SNPs did not influence survival under a co-dominant model (Table 
2). Six SNPs were significant in the univariate analyses, of which three 
(rs16892766 at 8q23, rs9929218 at 16q22 and rs10795668 at 10p14) 
remained significant after correction for multiple testing (Table 2). We have 
previously shown that the WHO performance status, number of metastatic 
sites, white blood cell count, alkaline phosphatase levels and KRAS and 
BRAF mutation status are independent prognostic factors affecting survival in 
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patients from COIN (36). We therefore applied a multivariate model with these 
factors, together with the best genetic models that fitted the data, and showed 
that all three SNPs independently influenced survival (Supplementary Table 
S1). 
 
Validation phase 
We used samples from numerous independent trials and cohort studies to 
provide sufficient power to carry out our validation analyses. In total, we 
assayed rs16892766, rs9929218 and rs10795668 in 5552 patients with CRC 
(196 from COINB, 337 from FOCUS2, 172 from FOCUS3, 334 from 
PICCOLO, 918 from VICTOR, 259 from HPFS, 355 from NHS, 278 from PHS, 
531 from PLCO1, 478 from PLCO2, 281 from VITAL, 450 from WHI1 and 963 
from WHI2; Table 1). No significant heterogeneity was detected in any of the 
meta-analyses (I2=0%). Only rs9929218 was found to be significantly 
associated with survival (P=2.5x10-2, Supplementary Table S2). 
 
Further analyses of rs9929218 
Patients homozygous for the minor allele of rs9929218 (AA genotype), 
equating to ~8% of patients, showed significantly poorer survival as compared 
to patients with the AG or GG genotypes (training phase HR 1.47, 95% CI 
1.24-1.75, P=1.4x10-5 unadjusted, HR=1.43, 95% CI 1.20-1.71, P=5.8x10-5 
after adjustment for age, sex and time from diagnosis to randomisation; 
validation phase HR=1.19, 95% CI 1.02-1.38, P=2.5x10-2 unadjusted, 
HR=1.18, 95% CI 1.01-1.37, P=3.2x10-2 adjusted; combined HR=1.30 95% CI 
1.16-1.46, P=6.1x10-6 unadjusted, HR=1.28 95% CI 1.14-1.43, P=2.2x10-5 
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adjusted; Figure 1 and Table 3). This equated to a median decrease in life 
expectancy of 4.3 months (based on training phase data). Patients with a 
single variant allele (AG genotype) had similar survival outcomes to those with 
a wild type (GG) genotype (Supplementary Table S3). 
 
We combined the training and validation phase data and analysed by disease 
stage. rs9929218 genotype did not deviate from the HWE according to stage 
(Supplementary Table S4). rs9929218 was not significantly associated with 
survival amongst patients with Stage 1-3 (pre-metastatic) disease (HR=1.19, 
95% CI 0.93-1.52, P=0.18), with little statistical evidence of heterogeneity 
amongst the individual studies (P=0.39) (Figure 2). In contrast, rs9929218 
was highly associated with survival in patients with Stage 4 (metastatic) CRC 
(HR=1.34, 95% CI 1.17-1.53, P=2.7x10-5), with no heterogeneity amongst the 
individual trials and cohorts (P=0.91) (Figure 2). There was, however, no 
significant difference between the associations of rs9929218 genotype and 
survival in patients with Stage 1-3 and Stage 4 disease (Pinteraction= 0.48). 
 
As a sensitivity analysis, we investigated whether overall survival accurately 
reflected survival from the time of diagnosis to death. For 2444 trial patients 
(from COIN, COINB and FOCUS3) we had relevant clinical information 
available and we found little difference in the effect of rs9929218 between the 
two survival measures (overall survival HR=1.50, 95% CI 1.27-1.76, 
P=1.5x10-6; survival time from diagnosis HR=1.46, 95% CI 1.24–1.73, 
P=6.3x10-6, Supplementary Figure). 
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We also investigated whether the type and duration of treatment influenced 
survival, by evaluating rs9929218 according to trial arm in COIN (the largest 
trial for which we had high quality clinical data). We did not find significant 
heterogeneity between the treatment arms (P=0.38) suggesting that treatment 
did not influence the association between rs9929218 genotype and survival 
(Supplementary Table S5). 
 
We also sought whether rs9929218 was associated with response to 
treatment (likely to be correlated with survival). In COIN Arms A and C, 
treatment was identical for the first 12 weeks apart from the choice of 
fluoropyrimidine. At 12 weeks, patients from these arms that were 
homozygous for the rs9929218 minor allele had significantly worse response 
(36/112 responded, 32%), as compared to patients that were heterozygous or 
homozygous wild-type (626/1257 responded, 50%) (OR 0.47, 95% CI 0.31–
0.72, P=3.9x10-4, adjusted for choice of fluoropyrimidine) (Table 4). 
 
DISCUSSION 
The literature contains many reports of potential common inherited biomarkers 
of survival for CRC; however, most of these have been derived from poorly 
designed studies, with small numbers of samples and/or no validation of their 
results. As a consequence, very few of these prognostic biomarkers have 
been validated by independent groups. To address the critical shortcomings of 
previous studies, we have carried out an analysis using large independent 
training and validation phase cohorts as recommended by the REMARK 
guidelines (40) and produced robust evidence for the first common inherited 
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genetic variant affecting survival in patients with CRC. As such, this finding 
represents an important clinical milestone. 
 
Our data suggest that patients homozygous for the minor allele of rs9929218, 
equating to ~8% of patients, have worse survival, with a median decrease in 
life expectancy of ~4 months (in the advanced disease setting). Another study 
recently reported that the major allele of rs9929218 was associated with 
improved prognosis (30), providing further support for this variant having a 
genuine prognostic effect. Although the effect size of rs9929218 identified 
herein is modest (HR=1.28, 95% CI 1.14-1.43), the identification of further 
prognostic alleles by well-powered GWAS-based approaches may help 
clinicians model the combined effects of common germline variants together 
with their somatic mutation profiles to help inform patient outcome. Our study 
therefore represents a critical first step in this endeavour. 
 
We have shown a clear effect of rs9929218 on survival amongst patients with 
stage 4 disease. However, many of these patients would have received 
similar therapies raising the possibility that rs9929218 influences survival 
based upon an interaction with treatment, and we noted that patients carrying 
both minor alleles had poor response to chemotherapy. However, survival and 
response are likely to be related and we found similar prognostic effects 
across all arms of the COIN trial (including in those patients receiving 
intermittent therapy) and amongst many of the other trials and cohorts used in 
this study. These data suggest that the prognostic effect may therefore reflect 
an underlying influence on a biological process or pathway. rs9929218 lies 
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within intron 2 of CDH1 encoding E-cadherin, in strong LD with rs16260 (41) 
in the CDH1 promoter which down-regulates CDH1 expression (42). Patients 
homozygous for the minor allele of rs9929218 would be expected to have 
reduced E-cadherin expression. E-cadherin functions as a transmembrane 
glycoprotein that is critical in the establishment and maintenance of 
intercellular adhesion, cell polarity and tissue morphology and regeneration 
(43) and its loss represents a defining feature of the epithelial to mesenchymal 
transition during metastasis. A clear mechanism therefore exists for the 
potential prognostic effect of rs9929218 by influencing this process. 
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TABLES 
 
Table 1 – Clinical trial and population-based cohorts analysed in this study. 
 
 
 Training 
Phase  
Validation 
Phase 
  COIN  COINB FOCUS2 FOCUS3 PICCOLO VICTOR HPFS NHS PHS PLCO1 PLCO2 VITAL WHI1 WHI2 
No. cases with 
rs9929218 genotype 
 2078a  196 337 172 334 918 259 355 278 531 478 281 450 963 
GG 
GA 
AA 
 1061 
853 
164 
 
106 
73 
17 
170 
143 
24 
83 
75 
14 
170 
137 
27 
485 
361 
72 
128 
109 
22 
186 
132 
37 
134 
123 
21 
273 
217 
41 
261 
173 
44 
141 
112 
28 
217 
190 
43 
471 
399 
93 
      
Total no. deaths 
(% of cases) 
 1557 (75)  99 (51) 301 (89) 78 (45) 312 (93) 108 (12) 124 (48) 145 (41) 128 (46) 180 (34) 103 (22) 94 (33) 165 (37) 310 (32) 
GG 
GA 
AA 
 783 (74) 
634 (74) 
140 (85) 
 
58 (55) 
30 (41) 
11 (65) 
153 (90)
124 (87)
24 (100)
32 (39) 
38 (51) 
8 (57) 
159 (94) 
128 (93) 
25 (93) 
56 (12) 
41 (11) 
11 (15) 
65 (51) 
47 (43) 
12 (55) 
71 (38) 
64 (48) 
10 (27) 
67 (50) 
50 (41) 
11 (52) 
84 (31) 
79 (36) 
17 (41) 
62 (24)
34 (20)
7 (16) 
42 (30) 
37 (33) 
15 (54) 
77 (35) 
69 (36) 
19 (44) 
146 (31) 
133 (33) 
31 (33) 
      
Median follow-up (SD)  2.4 (2.2)  2.0 (4.4) 3.7 (n/a)b 1.0 (0.8) 3.0 (3.1) 5.3 (1.4) 5.0 (3.8) 5.4 (4.9) 9.3 (7.4) 6.7 (3.4) 3.4 (3.6) 3.6 (2.3) 5.2 (3.5) 2.9 (3.4) 
                 
% Female  34  42 37 37 34 65 0 100 0 43 43 47 100 100 
                 
Age at diagnosis, N (%)                 
<65 years 
65–69 
70–74 
75–79 
≥80 years 
Missing 
Mean (SD) 
 1203 (58) 
422 (20) 
318 (15) 
124 (6) 
9 (<1) 
2 (<1) 
62.0 (9.6) 
 
115 (59) 
35 (18) 
31 (16) 
10 (5) 
5 (3) 
0 (0) 
61.7 (10.4) 
39 (12) 
54 (16) 
104 (31)
94 (28) 
46 (14) 
0 (0) 
72.7 (7.1)
110 (64) 
32 (19) 
17 (10) 
13 (8) 
0 (0) 
0 (0) 
60.9 (10.0)
Not 
collected
Not 
collected
55 (21) 
32 (13) 
55 (21) 
53 (21) 
62 (24) 
2 (1) 
72.3 (8.7) 
115 (32)
75 (25) 
78 (22) 
60 (17) 
27 (8) 
0 (0) 
68.5 (7.7)
91 (33) 
42 (15) 
37 (13) 
43 (16) 
65 (23) 
0 (0) 
71.3 (9.8)
125 (24)
145 (27)
161 (30)
88 (17) 
12 (2) 
0 (0) 
69 (5.9) 
98 (21)
115 (24)
131 (27)
88 (18)
46 (10)
0 (0) 
70 (6.6)
51 (18) 
59 (20) 
90 (31) 
67 (23) 
14 (5) 
8 (3) 
70.4 (6.5)
87 (19) 
87 (19) 
133 (30)
96 (21) 
47 (10) 
0 (0) 
70.9 (7.1)
149 (16) 
205 (21) 
248 (26) 
199 (21) 
162 (17) 
0 (0) 
72.1 (7.2) 
                 
Stage (%)                 
1 
2-3 
4 
Unknown 
 0 (0) 
0 (0) 
2078 (100) 
0 (0) 
 
0 (0) 
0 (0) 
196 (100) 
0 (0) 
0 (0) 
0 (0) 
337 (100)
0 (0) 
0 (0) 
0 (0) 
172 (100) 
0 (0) 
0 (0) 
0 (0) 
334 (100)
0 (0) 
5 (1) 
913 (99)
0 (0) 
0 (0) 
72 (28) 
89 (34) 
33 (13) 
65 (25) 
78 (22) 
183 (52)
54 (15) 
40 (11) 
57 (21) 
108 (39)
24 (9) 
89 (32) 
193 (36)
282 (53)
51 (10) 
5 (1) 
166 (35)
246 (52)
65 (14)
1 (<1) 
105 (37) 
126 (45) 
46 (16) 
4 (1) 
126 (28)
252 (56)
66 (15) 
6 (1) 
293 (30) 
493 (51) 
123 (13) 
54 (6) 
                 
Tumour site, N (%)                 
Colonc 
Rectumd 
Unknown 
 1103 (53) 
951 (46) 
24 (1) 
 
124 (63) 
71 (36) 
1 (1) 
240 (71)
94 (28) 
3 (1) 
83 (48) 
86 (50) 
3 (2) 
225 (64) 
121 (34) 
7 (2) 
574 (63)
344 (37)
0 (0) 
173 (67) 
54 (21) 
32 (12) 
273 (77)
73 (21) 
9 (3) 
195 (70)
55 (20) 
28 (10) 
514 (97)
5 (1) 
12 (2) 
314 (66)
159 (33)
5 (1) 
211 (75) 
64 (23) 
6 (2) 
436 (97)
11 (2) 
3 (1) 
678 (70) 
232 (24) 
53 (6) 
Data provided for those samples with an rs9929218 genotype. aOf the 2083 COIN patients, 5 failed genotyping for rs9929218. bFollow-up never dropped below 50%, so figure 
represents the median time from patient entry to the cut-off date for analysis. cColon defined as cecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending 
colon and sigmoid colon. dRectum defined as rectosigmoid junction and rectum. 
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Table 2 - Univariate analyses of overall survival in our training phase cohort 
 
       aHR (95% CI)    
SNP locus n genotyped AA AB BB 
n 
deaths AB vs AA BB vs AA Χ
2 P-value CorrectedP 
rs4939827 18q21 2068 637 1028 403 1552 1.00 (0.89-1.12) 1.02 (0.88-1.17) 0.06 0.97 - 
rs16892766 8q23 2079 1688 378 13 1557 1.28 (1.13-1.45) 1.26 (0.67-2.35) 15.14 5.2x10-4 1.0x10-2 
rs4779584 15q13 2070 1245 710 115 1554 0.97 (0.87-1.08) 0.96 (0.77-1.19) 0.36 0.84 - 
rs6983267 8q24 2065 674 979 412 1549 1.01 (0.90-1.14) 1.15 (1.00-1.32) 4.41 0.11 - 
rs11169552 12q13 2002 1086 785 131 1506 0.91 (0.82-1.01) 0.92 (0.75-1.14) 3.28 0.19 - 
rs7136702 12q13 1964 807 868 289 1474 1.00 (0.89-1.11) 1.15 (0.98-1.34) 3.63 0.16 - 
rs6691170 1q41 2070 760 1019 291 1554 1.01 (0.90-1.12) 0.89 (0.76-1.04) 2.56 0.28 - 
rs6687758 1q41 2066 1302 666 98 1551 0.92 (0.83-1.03) 0.97 (0.78-1.22) 2.08 0.35 - 
rs10936599 3q26.2 2070 1218 739 113 1554 0.99 (0.89-1.10) 1.09 (0.87-1.36) 0.61 0.74 - 
rs4925386 20q13 2061 973 886 202 1544 0.92 (0.83-1.02) 0.88 (0.74-1.05) 3.48 0.18 - 
rs4444235 14q22 2066 571 1008 487 1552 1.00 (0.89-1.12) 0.92 (0.80-1.05) 1.93 0.38 - 
rs9929218 16q22 2078 1061 853 164 1557 1.01 (0.91-1.12) 1.47 (1.23-1.76) 18.79 8.3x10-5 1.7x10-3 
rs10411210 19q13 2070 1686 360 24 1554 1.24 (1.09-1.41) 0.94 (0.58-1.52) 10.81 4.5x10-3 0.09 
rs961253 20p12 2069 808 972 289 1553 1.04 (0.93-1.16) 1.00 (0.85-1.16) 0.65 0.72 - 
rs10795668 10p14 1993 940 868 185 1491 0.95 (0.86-1.06) 0.70 (0.58-0.85) 12.42 2.0x10-3 4.0x10-2 
rs3802842 11q23 2070 993 870 207 1554 0.98 (0.88-1.09) 1.13 (0.96-1.34) 2.61 0.27 - 
rs1957636 14q22 2069 656 1029 384 1554 0.99 (0.88-1.10) 0.95 (0.82-1.09) 0.59 0.74 - 
rs4813802 20p12 2051 795 958 298 1543 0.86 (0.77-0.96) 1.01 (0.87-1.18) 9.26 9.8x10-3 0.196 
rs16969681 15q13 2060 1637 394 29 1544 1.04 (0.92-1.18) 1.35 (0.92-2.00) 2.61 0.27 - 
rs11632715 15q13 2063 535 1034 494 1548 0.86 (0.76-0.97) 0.97 (0.85-1.12) 7.47 2.4x10-2 0.48 
 
Analyses used a Cox proportional-hazard model (co-dominant analyses) with the outcome of overall survival, adjusted for treatment arm and 
chemotherapy regimen (P-value) and corrected for multiple testing (corrected P-value). aThe co-dominant model tests for the joint effect of AB vs AA 
and BB vs AA. n values give the numbers of patients with their respective genotypes and for whom survival data was available. Note – rs4939827, 
rs961253, rs6983267 and rs4444235 have all been previously associated with survival (27-29,31,32), but none were validated in our study.
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Table 3 - Univariate analysis of rs9929218 on survival according to 
training phase, validation phase and combined 
 
 
Analysis 
phase Alleles n genotyped n deaths HR (95% CI) P-value 
      
Training 
phase 
GG/GA 1913 1416 1.43 (1.20-1.71) 5.8x10-5 AA 163 139 
      
Validation 
phase 
GG/GA 5069 1946 1.18 (1.01-1.37) 3.2x10-2 AA 483 201 
      
Combined GG/GA 6982 3362 1.28 (1.14-1.43) 2.2x10-5 AA 646 340 
 
Data are shown for recessive analyses with P-values adjusted for age, sex 
and time of diagnosis. HRs for the validation phase and the combined 
analysis are pooled effects using fixed-effects inverse-variance meta-analysis.  
 
 
 
Table 4 - Prognostic effect of rs9929218 on response to chemotherapy 
 
Outcome GG/AG n (%) 
AA 
n (%) P-value 
    
Response 626 (49.8) 36 (32.1) χ2=12.8, 1 d.f. 
P=3.9x10-4    No response 631 (50.2) 76 (67.9) 
 
Patients were from Arms A and C of COIN in which treatment was identical for 
the first 12 weeks apart from the choice of fluoropyrimidine. P-value is 
adjusted for choice of fluoropyrimidine. 
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Legends to Figures 
Figure 1 – Forest plot of rs9929218 analysed for survival in the training phase, 
validation phase and all data combined (adjusted for age, sex and time of 
diagnosis). 
 
Figure 2 - Forest plot of rs9929218 analysed for survival and stratified by 
disease stage (adjusted for age, sex and time of diagnosis). 
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